Quarter
Charts

enVVeno Medical Corporation

NVNO

CIK 0001661053 · Quarterly mode · latest period FY2022 (Q4) (ending 2022-12-31) · sourced from SEC EDGAR

At a glance · FY2022 (Q4)

Revenue
$147K
↑+2947.3% +$142Kvs FY2021 (Q4)
Gross Profit
$147K
↑+2947.3% +$142Kvs FY2021 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -47.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 13.58 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.00x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +2947.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$0
investment in PP&E
Stock-based comp (TTM)
$3M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$30M
everything owned
Total liabilities
$2M
everything owed
Stockholders' equity
$27M
shareholder claim

Recent performance · 36 quarters

Revenue↑+2947.3% +$142K
$147K
Net Income↑+19.5% +$1M
$-5M
Free Cash Flow↑+100.0% +$4K
$0
Operating Margin↑+280968.1pts
-59862.9%

Drill down

NVNO Sankey

See enVVeno Medical Corporation's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

NVNO Charts

36 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

NVNO Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics